Kodiak Sciences

Kodiak Sciences is a clinical stage biopharma company dedicated to the research, development, and commercialization of transformative therapeutics for high prevalence retinal diseases. The company's ABC Platform™ integrates antibody-based and chemistry-based therapies, serving as the foundation for Kodiak's discovery engine. Their lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate designed to address retinal vascular diseases, including wet age-related macular degeneration and diabetic eye diseases. Kodiak has leveraged its ABC Platform to construct a pipeline of product candidates, including KSI-501, a dual inhibitor antibody biopolymer conjugate targeting VEGF and IL-6 for the treatment of retinal diseases. The company is also expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Founded in 2009, Kodiak Sciences operates in the biotechnology, health care, and health and wellness sectors, with its headquarters situated in the United States. The company's culture is marked by curiosity, creativity, compassion, and courage, with a collective goal to make a difference in the world. Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance for its employees. The company is located in Palo Alto, at the heart of the world-class biotech hub of Silicon Valley, within walking distance to California Avenue’s shops, restaurants, and public transportation. As of now, there is no publicly available information regarding the company's last investment or the associated investors.